Investigational drug · Phase 3
QL0911
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Cancer Treatment-Induced Thrombocytopenia, Thrombocytopenia, Immune.
Phase 3Last checked: Nov 19, 2026Latest source record: Sep 9, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
5
Any phase or sponsor naming "QL0911"
First trial start
2024
Oct 22, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "QL0911", any sponsor or status.
Conditions studied
As listed on its trial records.
- Cancer Treatment-Induced Thrombocytopenia
- Thrombocytopenia, Immune
Approved drugs for the same conditions: Oncology · Hematology and blood cancers · Cardiovascular and metabolic
Largest trials
Live from ClinicalTrials.gov: studies naming "QL0911" as an intervention, largest first.
- QL0911 for the Treatment of Cancer Treatment-Induced ThrombocytopeniaPivotal-lookingRecruiting
Qilu Pharmaceutical Co., Ltd.Industry
NCT06456528 · 235 participants (planned) · Start Oct 22, 2024 · Primary completion Apr 30, 2027
Drug: QL0911; QL0911 plus Placebo and 1 more · For: Cancer Treatment-Induced Thrombocytopenia
Sites: Harbin, China; Nanjing, China
- Efficacy and Safety of QL0911 in Adult Patients With Chronic Primary Immune ThrombocytopeniaPivotal-lookingCompleted
Qilu Pharmaceutical Co., Ltd.Industry
NCT05621330 · 216 participants · Start Oct 18, 2019 · Primary completion Dec 13, 2021
Drug: QL0911; Placebo comparator · For: Primary Immune Thrombocytopenia
Sites: Shandong, China
- Evaluating the Efficacy and Safety of QL0911 in the Prevention of Chemotherapy- Induced ThrombocytopeniaPivotal-lookingCompleted
Qilu Pharmaceutical Co., Ltd.Industry
NCT05554913 · 63 participants · Start Nov 8, 2022 · Primary completion Feb 20, 2024
Drug: QL0911; Placebo · For: Chemotherapy-induced Thrombocytopenia
Sites: Shanghai, China
- Safety and Efficacy Study of QL0911 to Treat Immune Thrombocytopenia (ITP) in Pediatric PatientsPivotal-lookingNot yet recruiting
Qilu Pharmaceutical Co., Ltd.Industry
NCT07455006 · 60 participants (planned) · Start Apr 20, 2026 · Primary completion Dec 10, 2027
Drug: QL0911; Placebo · For: Thrombocytopenia, Immune
- Evaluating the Efficacy and Safety of QL0911 in Chemotherapy- Induced ThrombocytopeniaPivotal-lookingCompleted
Qilu Pharmaceutical Co., Ltd.Industry
NCT05851027 · 50 participants · Start Jan 15, 2021 · Primary completion Sep 10, 2021
Drug: QL0911 · For: Chemotherapy-induced Thrombocytopenia
Sites: Shanghai, China
Newest research
PubMed records naming it or its code names, newest first.
- [Efficacy and safety of romiplostim N01 for refractory aplastic anemia: a retrospective single-center study].
Zhuang QL, Liu ZW, Yang C, et al. · Zhonghua Xue Ye Xue Za Zhi 2026
- Efficacy and safety of QL0911 in adult patients with chronic primary immune thrombocytopenia: A multicenter, randomized, double-blind, placebo-controlled, phase III trial.
Zhou H, Han S, Jin J, et al. · J Transl Int Med 2023
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.